Combinatorial drug approaches to tackle Candida albicans biofilms

References

• Lim CS-Y, Rosli R, Seow HF, Chong PP. Candida and invasive candidiasis: back to basics. Eur J Clin Microbiol Infect Dis 2012;31:21-31
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med 2012;4:165rv13
   PubMed Web of Science ®Google Scholar
• Nett JE. Future directions for anti-biofilm therapeutics targeting Candida. Expert Rev Anti Infect Ther 2014;12:375-82
   PubMed Web of Science ®Google Scholar
• Cuéllar-Cruz M, Vega-González A, Mendoza-Novelo B, et al. The effect of biomaterials and antifungals on biofilm formation by Candida species: A review. Eur J Clin Microbiol Infect Dis 2012;31:2513-27
   PubMed Web of Science ®Google Scholar
• Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence 2013;4:119-28
   PubMed Web of Science ®Google Scholar
• Tobudic S, Kratzer C, Lassnigg A, Presterl E. Antifungal susceptibility of Candida albicans in biofilms. Mycoses 2012;55:199-204
   PubMed Web of Science ®Google Scholar
• Cuéllar-Cruz M, López-Romero E, Villagómez-Castro JC, Ruiz-Baca E. Candida species: new insights into biofilm formation. Future Microbiol 2012;7:755-71
   PubMed Web of Science ®Google Scholar
• Delattin N, Cammue B, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem 2014;6:77-90
   PubMed Web of Science ®Google Scholar
• Sherry L, Rajendran R, Lappin DF, et al. Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol 2014;14:182
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Fiori B, Trecarichi EM, et al. Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. PLoS One 2012;7:e33705
   PubMedGoogle Scholar
• Van Acker H, Van Dijck P, Coenye T. Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol 2014;22:326-33
   PubMed Web of Science ®Google Scholar
• Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog 2012;8:e1002585
   PubMed Web of Science ®Google Scholar
• Lattif AA, Chandra J, Chang J, et al. Proteomics and Pathway Mapping Analyses Reveal Phase-Dependent Over-Expression of Proteins Associated with Carbohydrate Metabolic Pathways in Candida albicans Biofilms. Open Proteomics J 2008;1:5-26
   Google Scholar
• Lattif AA, Mukherjee PK, Chandra J, et al. Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology 2011;157:3232-42
   PubMed Web of Science ®Google Scholar
• Vialás V, Perumal P, Gutierrez D, et al. Cell surface shaving of Candida albicans biofilms, hyphae, and yeast form cells. Proteomics 2012;12:2331-9
   PubMed Web of Science ®Google Scholar
• Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics 2006;6:5795-804
   PubMed Web of Science ®Google Scholar
• Seneviratne CJ, Wang Y, Jin L, et al. Candida albicans biofilm formation is associated with increased anti-oxidative capacities. Proteomics 2008;8:2936-47
   PubMed Web of Science ®Google Scholar
• Fox EP, Bui CK, Nett JE, et al. An expanded regulatory network temporally controls Candida albicans biofilm formation. Mol Microbiol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• García-Sánchez S, Aubert S, Iraqui I, et al. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 2004;3:536-45
   PubMed Web of Science ®Google Scholar
• Murillo LA, Newport G, Lan CY, et al. Genome-wide transcription profiling of the early phase of biofilm formation by Candida albicans. Eukaryot Cell 2005;4:1562-73
   PubMed Web of Science ®Google Scholar
• Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012;148:126-38
   PubMed Web of Science ®Google Scholar
• Nett JE, Lepak AJ, Marchillo K, Andes DR. Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis 2009;200:307-13
   PubMed Web of Science ®Google Scholar
• Zarnowski R, Westler WM, Lacmbouh GA, et al. Novel entries in a fungal biofilm matrix encyclopedia. MBio 2014;5:e01333-14
   PubMed Web of Science ®Google Scholar
• Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 2010;8:623-33
   PubMed Web of Science ®Google Scholar
• Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 2010;54:3505-8
   PubMed Web of Science ®Google Scholar
• Vediyappan G, Rossignol T, d’Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob Agents Chemother 2010;54:2096-111
   PubMed Web of Science ®Google Scholar
• Taff HT, Nett JE, Zarnowski R, et al. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog 2012;8:e1002848
   PubMed Web of Science ®Google Scholar
• Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 2012;55:80-5
   PubMed Web of Science ®Google Scholar
• Rajendran R, Sherry L, Lappin DF, et al. Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation. BMC Microbiol 2014;14:303
   PubMed Web of Science ®Google Scholar
• Huang G. Regulation of phenotypic transitions in the fungal pathogen Candida albicans. Virulence 2012;3:251-61
   PubMed Web of Science ®Google Scholar
• Miller MG, Johnson AD. White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell 2002;110:293-302
   PubMed Web of Science ®Google Scholar
• Morschhäuser J. Regulation of white-opaque switching in Candida albicans. Med Microbiol Immunol 2010;199:165-72
   PubMed Web of Science ®Google Scholar
• Daniels KJ, Srikantha T, Lockhart SR, et al. Opaque cells signal white cells to form biofilms in Candida albicans. EMBO J 2006;25:2240-52
   PubMed Web of Science ®Google Scholar
• Alby K, Bennett RJ. Interspecies pheromone signaling promotes biofilm formation and same-sex mating in Candida albicans. Proc Natl Acad Sci USA 2011;108:2510-15
   PubMed Web of Science ®Google Scholar
• Tao L, Cao C, Liang W, et al. White cells facilitate opposite- and same-sex mating of opaque cells in Candida albicans. PLoS Genet 2014;10:e1004737
   PubMed Web of Science ®Google Scholar
• Si H, Hernday AD, Hirakawa MP, et al. Candida albicans white and opaque cells undergo distinct programs of filamentous growth. PLoS Pathog 2013;9:e1003210
   PubMed Web of Science ®Google Scholar
• Soll DR. The role of phenotypic switching in the basic biology and pathogenesis of Candida albicans. J Oral Microbiol 2014;6
   PubMed Web of Science ®Google Scholar
• Kvaal CA, Srikantha T, Soll DR. Misexpression of the white-phase-specific gene WH11 in the opaque phase of Candida albicans affects switching and virulence. Infect Immun 1997;65:4468-75
   PubMed Web of Science ®Google Scholar
• Kvaal C, Lachke SA, Srikantha T, et al. Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous infection. Infect Immun 1999;67:6652-62
   PubMed Web of Science ®Google Scholar
• Geiger J, Wessels D, Lockhart SR, Soll DR. Release of a Potent Polymorphonuclear Leukocyte Chemoattractant Is Regulated by White-Opaque Switching in Candida albicans. Infect Immun 2004;72:667-77
   PubMed Web of Science ®Google Scholar
• Sasse C, Hasenberg M, Weyler M, et al. White-opaque switching of Candida albicans allows immune evasion in an environment-dependent fashion. Eukaryot Cell 2013;12:50-8
   PubMed Web of Science ®Google Scholar
• Tao L, Du H, Guan G, et al. Discovery of a ‘white-gray-opaque’ tristable phenotypic switching system in candida albicans: roles of non-genetic diversity in host adaptation. PLoS Biol 2014;12:e1001830
   PubMed Web of Science ®Google Scholar
• Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67:400-28
   PubMed Web of Science ®Google Scholar
• Ramage G, Bachmann S, Patterson TF, et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002;49:973-80
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003;71:4333-40
   PubMed Web of Science ®Google Scholar
• Shah AH, Singh A, Dhamgaye S, et al. Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans. Biochem J 2014;460:223-35
   PubMed Web of Science ®Google Scholar
• Li R, Kumar R, Tati S, et al. Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity. Antimicrob Agents Chemother 2013;57:1832-9
   PubMed Web of Science ®Google Scholar
• Lewis K. Persister cells: molecular mechanisms related to antibiotic tolerance. Handb Exp Pharmacol 2012;121-33
   PubMedGoogle Scholar
• LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006;50:3839-46
   PubMed Web of Science ®Google Scholar
• Sun J, Liu X, Jiang G, Qi Q. Inhibition of Nucleic Acid Biosynthesis Makes Little Difference to Formation of Amphotericin B-Tolerant Persisters in Candida albicans Biofilm. Antimicrob Agents Chemother 2015;59:1627-33
   PubMedGoogle Scholar
• Lafleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 2010;54:39-44
   PubMed Web of Science ®Google Scholar
• Bink A, Vandenbosch D, Coenye T, et al. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob Agents Chemother 2011;55:4033-7
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Kondo K, Uehara N, et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob Agents Chemother 2002;46:3113-17
   PubMed Web of Science ®Google Scholar
• Francois IEJA, Cammue BPA, Borgers M, et al. Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-Infect Agents Med Chem 2006;5:3-13
   Google Scholar
• Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: Endogenous ROS augmentation. J Proteome Res 2009;8:5296-304
   PubMed Web of Science ®Google Scholar
• Yan L, Li M, Cao Y, et al. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. J Antimicrob Chemother 2009;64:764-73
   PubMed Web of Science ®Google Scholar
• Vandenbosch D, Braeckmans K, Nelis HJ, Coenye T. Fungicidal activity of miconazole against Candida spp. biofilms. J Antimicrob Chemother 2010;65:694-700
   PubMed Web of Science ®Google Scholar
• Kim JH, Chan KL, Faria NCG, et al. Targeting the oxidative stress response system of fungi with redox-potent chemosensitizing agents. Front Microbiol 2012;3:88
   PubMed Web of Science ®Google Scholar
• François IE, Thevissen K, Pellens K, et al. Design and synthesis of a series of piperazine-1-carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species. ChemMedChem 2009;4:1714-21
   PubMed Web of Science ®Google Scholar
• Thevissen K, Hillaert U, Meert EMK, et al. Fungicidal activity of truncated analogues of dihydrosphingosine. Bioorg Med Chem Lett 2008;18:3728-30
   PubMed Web of Science ®Google Scholar
• Kim JH, Faria NCG, Martins MDL, et al. Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and cryptococcus with natural dihydroxybenzaldehydes. Front Microbiol 2012;3:261
   PubMed Web of Science ®Google Scholar
• Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 2012;109:2234-9
   PubMed Web of Science ®Google Scholar
• Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 2014;10:400-6
   PubMed Web of Science ®Google Scholar
• Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 2010;35:13-18
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51
   PubMed Web of Science ®Google Scholar
• Chen SCA, Sorrell TC. Antifungal agents. Med J Aust 2007;187:404-9
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80
   PubMed Web of Science ®Google Scholar
• Bink A. Anti-Biofilm Strategies: How to Eradicate Candida Biofilms? Open Mycol J 2011;5:29-38
   Google Scholar
• Fohrer C, Fornecker L, Nivoix Y, et al. Antifungal combination treatment: a future perspective. Int J Antimicrob Agents 2006;27:25-30
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination Treatment of Invasive Fungal Infections Combination Treatment of Invasive Fungal Infections. Clin Microbiol Rev 2005;18:163-94
   PubMed Web of Science ®Google Scholar
• Johnson MD, Macdougall C, Ostrosky-zeichner L, et al. MINIREVIEW Combination Antifungal Therapy. 2004;48:693-715
   Google Scholar
• Khan MSA, Ahmad I. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms. J Antimicrob Chemother 2012;67:618-21
   PubMed Web of Science ®Google Scholar
• Pemmaraju SC, Pruthi PA, Prasad R, Pruthi V. Candida albicans biofilm inhibition by synergistic action of terpenes and fluconazole. 2013;51:1032-7
   Google Scholar
• Ahmad A, Khan A, Akhtar F, et al. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida. Eur J Clin Microbiol Infect Dis 2011;30:41-50
   PubMed Web of Science ®Google Scholar
• Wei GX, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch Oral Biol 2011;56:565-72
   PubMed Web of Science ®Google Scholar
• Park KS, Kang KC, Kim JH, et al. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in Candida albicans. J Antimicrob Chemother 1999;43:667-74
   PubMed Web of Science ®Google Scholar
• Shi W, Chen Z, Chen X, et al. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: An in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Res 2010;10:885-93
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang C, Lu C, et al. Synergistic effect of doxycycline and fluconazole against Candida albicans biofilms and the impact of calcium channel blockers. FEMS Yeast Res 2013;13:453-62
   PubMed Web of Science ®Google Scholar
• Fiori A, Van Dijck P. Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother 2012;56:3785-96
   PubMed Web of Science ®Google Scholar
• Miceli MH, Bernardo SM, Lee SA. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 2009;34:326-32
   PubMed Web of Science ®Google Scholar
• Gao Y, Li H, Liu S, et al. Synergistic effect of fluconazole and doxycycline against Candida albicans biofilms resulting from calcium fluctuation and downregulation of fluconazole-inducible efflux pump gene overexpression. J Med Microbiol 2014;63:956-61
   PubMed Web of Science ®Google Scholar
• Shinde RB, Raut JS, Chauhan NM, Karuppayil SM. Chloroquine sensitizes biofilms of Candida albicans to antifungal azoles. Brazilian J Infect Dis 2013;17:395-400
   PubMed Web of Science ®Google Scholar
• Emerson LR, Nau ME, Martin RK, et al. Relationship between chloroquine toxicity and iron acquisition in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002;46:787-96
   PubMed Web of Science ®Google Scholar
• Prasad T, Chandra A, Mukhopadhyay CK, Prasad R. Unexpected link between iron and drug resistance of Candida spp.: Iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob Agents Chemother 2006;50:3597-606
   PubMed Web of Science ®Google Scholar
• De Cremer K, Lanckacker E, Cools TL, et al. Artemisinins, New Miconazole Potentiators Resulting in Increased Activity against Candida albicans Biofilms. Antimicrob Agents Chemother 2015;59:421-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. 2nd edition. 2010
   Google Scholar
• LaFleur MD, Lucumi E, Napper AD, et al. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 2011;66:820-6
   PubMed Web of Science ®Google Scholar
• Fábry S, Gáborová S, Bujdáková H, et al. Inhibition of germ tube formation, filamentation and ergosterol biosynthesis in Candida albicans treated with 6-amino-2-n-pentylthiobenzothiazole. Folia Microbiol (Praha) 1999;44:523-6
   PubMed Web of Science ®Google Scholar
• Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52:1127-32
   PubMed Web of Science ®Google Scholar
• Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 2011;7:e1002257
   PubMed Web of Science ®Google Scholar
• Shinde RB, Chauhan NM, Raut JS, Karuppayil SM. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann Clin Microbiol Antimicrob 2012;11:27
   PubMed Web of Science ®Google Scholar
• Chen YL, Lehman VN, Averette AF, et al. Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans. PLoS One 2013;8:e57672
   PubMed Web of Science ®Google Scholar
• Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005;309:2185-9
   PubMed Web of Science ®Google Scholar
• Singh SD, Robbins N, Zaas AK, et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009;5:e1000532
   PubMed Web of Science ®Google Scholar
• Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002;68:5459-63
   PubMed Web of Science ®Google Scholar
• Katragkou A, McCarthy M, Alexander EL, et al. In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J Antimicrob Chemother 2015;70:470-8
   PubMed Web of Science ®Google Scholar
• Yu LH, Wei X, Ma M, et al. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob Agents Chemother 2012;56:770-5
   PubMed Web of Science ®Google Scholar
• Jabra-Rizk MA, Shirtliff M, James C, Meiller T. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res 2006;6:1063-73
   PubMed Web of Science ®Google Scholar
• Delattin N, De Brucker K, Craik DJ, et al. The plant-derived decapeptide OSIP108 interferes with Candida albicans biofilm formation without affecting cell viability. Antimicrob Agents Chemother 2014;58:2647-56
   PubMed Web of Science ®Google Scholar
• De Brucker K, Delattin N, Robijns S, et al. Derivatives of the mouse cathelicidin-related antimicrobial peptide (CRAMP) inhibit fungal and bacterial biofilm formation. Antimicrob Agents Chemother 2014;58:5395-404
   PubMed Web of Science ®Google Scholar
• Troskie AM, Rautenbach M, Delattin N, et al. Synergistic activity of the tyrocidines, antimicrobial cyclodecapeptides from Bacillus aneurinolyticus, with amphotericin B and caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2014;58:3697-707
   PubMed Web of Science ®Google Scholar
• Delattin N, De Brucker K, Vandamme K, et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J Antimicrob Chemother 2014;69:1035-44
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990;81:1260-70
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6:181-202
   PubMed Web of Science ®Google Scholar
• Ehsanian R, Van Waes C, Feller SM. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine’s therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011;9:13
   PubMed Web of Science ®Google Scholar
• Kulkarny V V, Chavez-Dozal A, Rane HS, et al. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH. Antimicrob Agents Chemother 2014;58:7501-9
   PubMed Web of Science ®Google Scholar
• Bink A, Kucharíková S, Neirinck B, et al. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against candida albicans biofilms. J Infect Dis 2012;206:1790-7
   PubMed Web of Science ®Google Scholar
• You J, Du L, King JB, et al. Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates. ACS Chem Biol 2013;8:840-8
   PubMed Web of Science ®Google Scholar
• Thibane VS, Kock JLF, Van Wyk PWJ, et al. Stearidonic acid acts in synergism with amphotericin B in inhibiting Candida albicans and Candida dubliniensis biofilms in vitro. Int J Antimicrob Agents 2012;40:284-5
   PubMed Web of Science ®Google Scholar
• Thibane VS, Ells R, Hugo A, et al. Polyunsaturated fatty acids cause apoptosis in C. albicans and C. dubliniensis biofilms. Biochim Biophys Acta 2012;1820:1463-8
   PubMed Web of Science ®Google Scholar
• De Brucker K, Bink A, Meert E, et al. Potentiation of antibiofilm activity of amphotericin B by superoxide dismutase inhibition. Oxid Med Cell Longev 2013;2013:704654
   PubMedGoogle Scholar
• Zhou Y, Wang G, Li Y, et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob Agents Chemother 2012;56:3250-60
   PubMed Web of Science ®Google Scholar
• Stepanović S, Vuković D, Jesić M, Ranin L. Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida species. J Chemother 2004;16:134-8
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-throughput nano-biofilm microarray for antifungal drug discovery. MBio 2013;4:e00331-13
   PubMedGoogle Scholar
• Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp 2012;e3845
   PubMedGoogle Scholar
• Sekhon BS. Repositioning drugs and biologics: Retargeting old/ existing drugs for potential new therapeutic applications. 2013;4:1-15
   Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1
   PubMed Web of Science ®Google Scholar
• Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol 1939;26:585-615
   Google Scholar
• Liewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-90
   PubMed Web of Science ®Google Scholar
• Zhao W, Sachsenmeier K, Zhang L, et al. A New Bliss Independence Model to Analyze Drug Combination Data. J Biomol Screen 2014;19:817-21
   PubMed Web of Science ®Google Scholar
• Zhuang L, Sy SKB, Xia H, et al. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 2015;45:151-60
   PubMed Web of Science ®Google Scholar
• Kashif M, Andersson C, Åberg M, et al. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses. Mol Cancer Ther 2014;13:1964-76
   PubMed Web of Science ®Google Scholar
• Novick SJ. A simple test for synergy for a small number of combinations. Stat Med 2013;32:5145-55
   PubMed Web of Science ®Google Scholar
• Ren P, Luo M, Lin S, et al. Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint. Antimicrob Agents Chemother 2015;59:1759-66
   PubMedGoogle Scholar